IDenta Corp. Announces Entry Into the Chinese Market

JERUSALEM, September 13, 2016 /PRNewswire/ --

Mr. Nash Abramov, the newly appointed CEO of IDenta Corp (OTC PINK: IDTA) a developer of proprietary on-site drug, precursor of drug and explosive detection kits, announced today significant progress in penetrating the Chinese market. "The Chinese market is enormous and challenging and we have made a number of significant steps. Today at a government agency in China, our product demonstration was extremely successful," said Mr. Abramov.

About IDenta Corp. 

Since 2002, IDenta Corporation and its subsidiary IDenta Ltd recognized as a worldwide leader in the development of proprietary on-site Drug, Precursor of Drug and Explosive detection kits. IDenta develops, manufactures and distributes revolutionary products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

Disclaimer 

Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Contact
Amichai Glattstein, COO
T: +972-2-5872220
E: amichai@identa-corp.com 

SOURCE Identa Corp

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.